News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,646 Results
Type
Article (43926)
Company Profile (467)
Press Release (698237)
Multimedia
Podcasts (132)
Webinars (23)
Section
Business (209399)
Career Advice (2042)
Deals (36173)
Drug Delivery (128)
Drug Development (84040)
Employer Resources (174)
FDA (16748)
Job Trends (15205)
News (354390)
Policy (33302)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2674)
Accelerated approval (45)
Adcomms (29)
Allergies (165)
Alliances (51113)
ALS (202)
Alzheimer's disease (1800)
Antibody-drug conjugate (ADC) (387)
Approvals (17031)
Artificial intelligence (626)
Autoimmune disease (230)
Automation (50)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (205)
Biotechnology (329)
Bladder cancer (182)
Brain cancer (67)
Breast cancer (700)
Cancer (5426)
Cardiovascular disease (464)
Career advice (1731)
Career pathing (40)
CAR-T (308)
CDC (55)
Celiac Disease (2)
Cell therapy (834)
Cervical cancer (41)
Clinical research (72091)
Collaboration (1985)
Company closure (4)
Compensation (1275)
Complete response letters (80)
COVID-19 (2786)
CRISPR (107)
C-suite (1007)
Cystic fibrosis (156)
Data (7117)
Decentralized trials (3)
Denatured (42)
Depression (163)
Dermatology (58)
Diabetes (551)
Diagnostics (6883)
Digital health (51)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (309)
Drug pricing (203)
Drug shortages (30)
Duchenne muscular dystrophy (284)
Earnings (92312)
Editorial (63)
Employer branding (21)
Employer resources (153)
Events (122057)
Executive appointments (1062)
FDA (20188)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1673)
Gene editing (230)
Generative AI (52)
Gene therapy (709)
GLP-1 (1059)
Government (4793)
Grass and pollen (6)
Guidances (397)
Healthcare (19248)
HIV (75)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (297)
Immuno-oncology (86)
Indications (156)
Infectious disease (3104)
Inflammatory bowel disease (211)
Inflation Reduction Act (17)
Influenza (131)
Intellectual property (277)
Interviews (316)
IPO (16938)
IRA (53)
Job creations (3716)
Job search strategy (1441)
JPM (67)
Kidney cancer (18)
Labor market (92)
Layoffs (587)
Leadership (36)
Legal (8030)
Liver cancer (98)
Longevity (28)
Lung cancer (729)
Lymphoma (411)
Machine learning (53)
Management (59)
Manufacturing (925)
MASH (184)
Medical device (13996)
Medtech (14073)
Mergers & acquisitions (20385)
Metabolic disorders (1457)
mRNA (198)
Multiple sclerosis (177)
NASH (20)
Neurodegenerative disease (407)
Neuropsychiatric disorders (104)
Neuroscience (3250)
Neurotech (1)
NextGen: Class of 2026 (6773)
Non-profit (4596)
Now hiring (73)
Obesity (699)
Opinion (298)
Ovarian cancer (185)
Pain (233)
Pancreatic cancer (259)
Parkinson's disease (352)
Partnered (34)
Patents (555)
Patient recruitment (598)
Peanut (61)
People (60653)
Pharmaceutical (81)
Pharmacy benefit managers (32)
Phase 1 (22671)
Phase 2 (31797)
Phase 3 (23494)
Pipeline (7086)
Policy (319)
Postmarket research (2602)
Preclinical (9684)
Press Release (67)
Prostate cancer (282)
Psychedelics (57)
Radiopharmaceuticals (321)
Rare diseases (1051)
Real estate (6067)
Recruiting (71)
Regulatory (25460)
Reports (54)
Research institute (2503)
Resumes & cover letters (355)
Rett syndrome (32)
RNA editing (22)
RSV (85)
Schizophrenia (167)
Series A (283)
Series B (210)
Service/supplier (11)
Sickle cell disease (114)
Special edition (27)
Spinal muscular atrophy (169)
Sponsored (46)
Startups (3816)
State (2)
Stomach cancer (19)
Supply chain (118)
Tariffs (85)
The Weekly (87)
Vaccines (1086)
Venture capital (106)
Weight loss (447)
Women's health (111)
Worklife (20)
Date
Today (123)
Last 7 days (662)
Last 30 days (2859)
Last 365 days (30964)
2026 (7879)
2025 (31062)
2024 (36290)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (756)
Alabama (94)
Alaska (7)
Arizona (337)
Arkansas (15)
Asia (40926)
Australia (6802)
California (12429)
Canada (3516)
China (1260)
Colorado (530)
Connecticut (539)
Delaware (366)
Europe (89911)
Florida (1849)
Georgia (396)
Hawaii (3)
Idaho (61)
Illinois (980)
India (79)
Indiana (561)
Iowa (24)
Japan (490)
Kansas (133)
Kentucky (46)
Louisiana (39)
Maine (73)
Maryland (1502)
Massachusetts (8998)
Michigan (347)
Minnesota (683)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (134)
New Hampshire (87)
New Jersey (3322)
New Mexico (31)
New York (3252)
North Carolina (1632)
North Dakota (9)
Northern California (6128)
Ohio (366)
Oklahoma (22)
Oregon (44)
Pennsylvania (2492)
Puerto Rico (25)
Rhode Island (51)
South America (1125)
South Carolina (74)
South Dakota (1)
Southern California (4856)
Tennessee (199)
Texas (1935)
United States (44133)
Utah (370)
Vermont (1)
Virginia (297)
Washington D.C. (81)
Washington State (1019)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
742,646 Results for "nutcracker therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics
July 14, 2025
·
4 min read
Press Releases
Nutcracker Therapeutics Unveils NMU-Symphony™ System for On-demand, Individualized Manufacture of RNA-based Personalized Therapeutics
June 3, 2025
·
3 min read
Press Releases
Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences
May 1, 2025
·
3 min read
Press Releases
Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as Company Continues Evolution as an RNA Therapeutics CRDMO
March 27, 2025
·
4 min read
Biotech Bay
Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting
Nutcracker Therapeutics, Inc. recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
June 5, 2024
·
3 min read
Biotech Bay
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024
Nutcracker Therapeutics, Inc. today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
March 12, 2024
·
2 min read
Biotech Bay
Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum
Nutcracker Therapeutics, Inc. today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago.
May 16, 2024
·
2 min read
Business
Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer.
January 8, 2024
·
2 min read
Biotech Bay
Nutcracker Therapeutics’ Research Partner, the University of California, San Francisco, Presents Foundational Prostate Cancer Data at AAI 2024
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.
May 15, 2024
·
4 min read
Drug Development
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
Nutcracker Therapeutics, Inc recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, NTX-470; and the other highlighting data on the immunomodulatory cytokine, LIGHT.
April 11, 2024
·
4 min read
1 of 74,265
Next
